SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
Commission File Number 0-28498
(Check one)
|_| Form 10-K and Form 10-KSB |_| Form 11-K
|_| Form 20-F |X| Form 10-Q and Form 10-QSB |_| Form N-SAR
For period ended: March 31, 2004
|_| Transition Report on Form 10-K and Form 10-KSB
|_| Transition Report on Form 20-F
|_| Transition Report on Form 11-K
|_| Transition Report on Form 10-Q and Form 10-QSB
|_| Transition Report on Form N-SAR
For the transition period ended _____________________________________________
Read Attached Instruction Sheet Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates__________________________
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
PART I
REGISTRANT INFORMATION
Full name of registrant: Paradigm Medical Industries, Inc.
Former name if applicable: _____________________________________________________
Address of principal executive office (Street and number):
2355 South 1070 West
Salt Lake City, Utah 84119
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 132b-25(b), theZT
following should be completed. (Check box if appropriate).
(a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or
expense.
|X| (b) The subject annual report, semi-annual report, transition
report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion
thereof, will be filed on or before the fifteenth calendar day
following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or portion thereof
will be filed on or before the fifth calendar day following
the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12(b)-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 11-K,
10-Q, N-SAR or the transition report or portion thereof, could not be filed
within the prescribed time period. (Attach extra sheets if needed.)
The Form 10-QSB cannot be completed within the requested time period
due to the additional time required to complete the unaudited financial
statements of Registrant, primarily as a result of the recent change in
Registrant's management resulting from the appointment by the Board of Directors
on March 18, 2004 of John Y. Yoon as Registrant's new President and Chief
Executive Officer, replacing Jeffrey Poore who had served in those positions
from March 19, 2003 to March 18, 2004.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Randall A. Mackey (801) 575-5000
-----(name)-------------------(area code)-----(telephone number)--------
(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months (or for such shorter) period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s).
|X|Yes |_| No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
If so, attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
|_|Yes |X| No
Paradigm Medical Industries, Inc.
---------------------------------
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.
Date: May 17, 2004 By: /s/ John Y. Yoon
--------------------------------------
John Y. Yoon
President and Chief Executive Officer